Adarx Pharma Shares Climb 30% After $446.3 Million Upsized IPO
Why now
Thesis: Biotech IPO demand shows risk appetite
Catalyst to watch: Aftermarket trading and follow-on deals
Main risk: Post-IPO pop may fade quickly
Why it matters
A strong upsized biotech IPO signals reopening risk appetite for new healthcare listings.
Related assets & topics
HealthcareSources
- googlenews · news.google.com · 2026-09-25 16:18 UTC
- googlenews · news.google.com · 2026-09-25 16:18 UTC